Proposed revisions to the classification of AxD include categories that exploit the supratentorial features of the early onset subtype and the bulbospinal features of late onset disease [5]. Reports of patients with AxD will continue to increase in the era of molecular testing and results will lend support to diagnostic schema based on phenotype rather than age.